Sökning: id:"swepub:oai:gup.ub.gu.se/279412" >
Dapagliflozin and C...
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
-
Wiviott, Stephen D (författare)
-
Raz, Itamar (författare)
-
Bonaca, Marc P (författare)
-
visa fler...
-
Mosenzon, Ofri (författare)
-
Kato, Eri T (författare)
-
Cahn, Avivit (författare)
-
Silverman, Michael G (författare)
-
Zelniker, Thomas A (författare)
-
Kuder, Julia F (författare)
-
Murphy, Sabina A (författare)
-
Bhatt, Deepak L (författare)
-
Leiter, Lawrence A (författare)
-
McGuire, Darren K (författare)
-
Wilding, John P H (författare)
-
Ruff, Christian T (författare)
-
Gause-Nilsson, Ingrid A M (författare)
-
Fredriksson, Martin (författare)
-
Johansson, Peter A (författare)
-
Langkilde, Anna-Maria (författare)
-
Sabatine, Marc S (författare)
-
- Dellborg, Mikael, 1954 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine
-
visa färre...
-
(creator_code:org_t)
- 2019
- 2019
- Engelska.
-
Ingår i: The New England journal of medicine. - 1533-4406. ; 380:4, s. 347-357
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined.We randomly assigned patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease to receive either dapagliflozin or placebo. The primary safety outcome was a composite of major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, or ischemic stroke. The primary efficacy outcomes were MACE and a composite of cardiovascular death or hospitalization for heart failure. Secondary efficacy outcomes were a renal composite (≥40% decrease in estimated glomerular filtration rate to <60 ml per minute per 1.73 m2 of body-surface area, new end-stage renal disease, or death from renal or cardiovascular causes) and death from any cause.We evaluated 17,160 patients, including 10,186 without atherosclerotic cardiovascular disease, who were followed for a median of 4.2 years. In the primary safety outcome analysis, dapagliflozin met the prespecified criterion for noninferiority to placebo with respect to MACE (upper boundary of the 95% confidence interval [CI], <1.3; P<0.001 for noninferiority). In the two primary efficacy analyses, dapagliflozin did not result in a lower rate of MACE (8.8% in the dapagliflozin group and 9.4% in the placebo group; hazard ratio, 0.93; 95% CI, 0.84 to 1.03; P=0.17) but did result in a lower rate of cardiovascular death or hospitalization for heart failure (4.9% vs. 5.8%; hazard ratio, 0.83; 95% CI, 0.73 to 0.95; P=0.005), which reflected a lower rate of hospitalization for heart failure (hazard ratio, 0.73; 95% CI, 0.61 to 0.88); there was no between-group difference in cardiovascular death (hazard ratio, 0.98; 95% CI, 0.82 to 1.17). A renal event occurred in 4.3% in the dapagliflozin group and in 5.6% in the placebo group (hazard ratio, 0.76; 95% CI, 0.67 to 0.87), and death from any cause occurred in 6.2% and 6.6%, respectively (hazard ratio, 0.93; 95% CI, 0.82 to 1.04). Diabetic ketoacidosis was more common with dapagliflozin than with placebo (0.3% vs. 0.1%, P=0.02), as was the rate of genital infections that led to discontinuation of the regimen or that were considered to be serious adverse events (0.9% vs. 0.1%, P<0.001).In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MACE than placebo but did result in a lower rate of cardiovascular death or hospitalization for heart failure, a finding that reflects a lower rate of hospitalization for heart failure. (Funded by AstraZeneca; DECLARE-TIMI 58 ClinicalTrials.gov number, NCT01730534 .).
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
Nyckelord
- Aged
- Benzhydryl Compounds
- adverse effects
- therapeutic use
- Cardiovascular Diseases
- etiology
- mortality
- prevention & control
- Diabetes Mellitus
- Type 2
- complications
- drug therapy
- Female
- Glucosides
- adverse effects
- therapeutic use
- Heart Failure
- epidemiology
- Hospitalization
- statistics & numerical data
- Humans
- Male
- Middle Aged
- Sodium-Glucose Transporter 2 Inhibitors
- adverse effects
- therapeutic use
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Wiviott, Stephen ...
-
Raz, Itamar
-
Bonaca, Marc P
-
Mosenzon, Ofri
-
Kato, Eri T
-
Cahn, Avivit
-
visa fler...
-
Silverman, Micha ...
-
Zelniker, Thomas ...
-
Kuder, Julia F
-
Murphy, Sabina A
-
Bhatt, Deepak L
-
Leiter, Lawrence ...
-
McGuire, Darren ...
-
Wilding, John P ...
-
Ruff, Christian ...
-
Gause-Nilsson, I ...
-
Fredriksson, Mar ...
-
Johansson, Peter ...
-
Langkilde, Anna- ...
-
Sabatine, Marc S
-
Dellborg, Mikael ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
- Artiklar i publikationen
-
The New England ...
- Av lärosätet
-
Göteborgs universitet